Seegene Inc (096530) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Seegene Inc stock KRW 23,309, price KRW 31,000, that is 24.8% below the price, quality 80 out of 100. Rating: overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 17,293 KRW – 77,176 KRW · fair‑value band 17,482 KRW – 29,136 KRW · the 31,000 KRW price screens above the 23,309 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Seegene in your weekly email
Every Wednesday you see whether Seegene is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Seegene, Inc. manufactures and sells molecular diagnostics products worldwide.
Show moreShow less
It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens detection products; tuberculosis detection products; drug resistance products; Magicplex sepsis real-time test for the detection and identification of sepsis causing pathogens; and meningitis detection products.
The company also provides other products for the detection of SNPs in factor II, factor V, and MTHFR genes. The company has a collaboration with Werfen for the joint development of syndromic qPCR assays. Seegene, Inc. was founded in 2000 and is headquartered in Seoul, South Korea.
Stock analysis
Seegene Inc (096530) currently trades at 31,000 KRW, while our model-based Fair Value estimate is 23,309 KRW, 25% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 29,101 KRW per share, and 5 of the 24 models we run sit above the 31,000 KRW price.
Bear case: the Dividend Discount group reads lowest at 8,073 KRW, and 19 of the 24 models stay below the price. Data coverage for this calculation is high.
Scenario range: 17,482 KRW (bear) to 29,136 KRW (bull), the price of 31,000 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 80/100 (high quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Seegene Inc reported revenue of 474B KRW in FY2025 versus 1.4T KRW in FY2021, a compound −23.3%/yr. Reported net income was 48.3B KRW in FY2025, compounding −45.2%/yr from FY2021.
Key figures
Market cap 1.4T KRW (≈ $1.0B) Small · P/E ratio 15.8 · P/S ratio 2.77 · EPS (TTM) 2,014 KRW · Dividend yield 3.9% · Net margin 18.0% · Return on equity 9.0% · Return on assets (EBIT) 11.1% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 54 out of 100 (low confidence).
What moves the price
The share trades about 20% below its 52-week high and 46% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −25%, 096530 screens richer than that median.
Fair Value models
Bear17,482 KRWFair Value 23,309 KRWBull29,136 KRW
Price 31,000 KRW · Downside -24.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (697.61 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+14.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−17.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−15.9%
Start year 2020 (pandemic). Over 10 years: +22.0% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−39.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−43.3%
Dividend (yield on the price)3.9%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−35.7% vs 18.3%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.60% → 7%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−3.6%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −5.5% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 13/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score80 · Top 25%
Fair Value upside−24.8% · Above median
Profitability
Return on equity (12 months)9.0% · Top 25%
Return on assets3.9% · Top 25%
Net margin (12 months)18.0% · Above median
Operating margin (12 months)15.9% · Above median
Growth and dividend
Revenue growth (quarter YoY)19.2% · Above median
Dividend yield (12 months)3.9% · Top 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Seegene Inc Fair Value". https://www.fairvalue-calculator.com/stock/096530
Frequently asked questions
Is Seegene Inc (096530) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 23,309 KRW versus a price of 31,000 KRW, about 25% lower (overvalued).
What is the fair value of 096530?
Our model-based fair value for Seegene Inc is 23,309 KRW (as of Nov 8, 2026), built from audited fundamentals. The current price: 31,000 KRW.
What is the quality score of 096530?
Seegene Inc has a Quality Score of 80/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Seegene Inc (096530)?
Our model-based price target is the fair value of 23,309 KRW (as of Nov 8, 2026) from 24 valuation models. Cautious scenario 17,482 KRW, optimistic scenario 29,136 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Seegene Inc stock forecast for 2026?
Our models put fair value at 23,309 KRW, about 25% lower versus a price of 31,000 KRW (overvalued). Cautious scenario 17,482 KRW, optimistic scenario 29,136 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Seegene Inc (096530)?
Seegene Inc reported trailing-twelve-month revenue of about 509B KRW (latest available figure, as of Nov 8, 2026).
Does Seegene Inc pay a dividend?
Seegene Inc currently shows a dividend yield of 3.87% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Seegene Inc (096530) and when is the ex-dividend date?
Seegene Inc pays a dividend of 1,200 KRW per share a year, a dividend yield of 3.9%. The last ex-dividend date was Jun 29, 2026. A dividend has been paid every year since at least 2019. The payout ratio is 59.6% of earnings. Free cash flow covers the dividend 1.99 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Seegene Inc (096530)?
For today's price to be fair in a discounted-cash-flow model, Seegene Inc would have to grow free cash flow by -3.6 % per year for five years (discount rate 11.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -15.9 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 096530 use?
Our models discount Seegene Inc at 11.3 %: a base by market capitalisation (small), damped by beta 0.90, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Seegene Inc that is -3.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.3 %) and the same formula as our fair value.
How much growth has Seegene Inc (096530) delivered so far?
Over the past 5 years revenue at Seegene Inc grew -15.9 % a year. The price currently implies free-cash-flow growth of -3.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Seegene Inc (096530) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Seegene Inc (-3.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Seegene Inc (096530)?
The free-cash-flow yield on the price is 7.71 %: that much free cash flow Seegene Inc produces per unit of market value. When it exceeds the discount rate of our models (11.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Seegene Inc (096530)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Seegene Inc it is 23,309 KRW per share (as of Nov 8, 2026), against a price of 31,000 KRW. It is the blended result of 24 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Seegene Inc stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 096530 trades above its calculated fair value: price 31,000 KRW, fair value 23,309 KRW, a gap of about −25% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 096530?
No. The price is what the market pays today (31,000 KRW); the fair value is what the company's own numbers justify (23,309 KRW). For Seegene Inc the two are 7,691 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Seegene Inc worth?
The market values Seegene Inc at about 1.4T KRW (market capitalisation, as of Nov 8, 2026). Per share that is 31,000 KRW; our models calculate a fair value of 23,309 KRW per share.
What do the bullish and bearish scenarios say about 096530?
Our models span a range for Seegene Inc: cautious scenario 17,482 KRW, base 23,309 KRW, optimistic 29,136 KRW per share (as of Nov 8, 2026, price 31,000 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 096530?
Seegene Inc trades at a price-to-earnings ratio of 15.8 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 23,309 KRW is built from several models across several years. Other multiples: P/B 1.4, P/S 2.8, EV/EBITDA 9.2.
How solid is the balance sheet of Seegene Inc (096530)?
Balance-sheet figures for Seegene Inc (as of Nov 8, 2026): return on equity 9.0%. They feed the Quality Score of 80/100, which measures business quality independently of the share price.
How far is 096530 from its 52-week high?
Seegene Inc trades at 31,000 KRW, about 20% below its 52-week high of 38,900 KRW and 46% above the low of 21,306 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 23,309 KRW is for.
Which stocks are comparable to Seegene Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Seegene Inc stock attractive at the current price?
The data as of Nov 8, 2026: price 31,000 KRW, calculated fair value 23,309 KRW (−25%), Quality Score 80/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 096530 calculated?
We run Seegene Inc through 24 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 23,309 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Seegene Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Seegene Inc (096530)?
The closing price on Nov 6, 2026 was 31,000 KRW. Our model-based fair value is 23,309 KRW, about 25% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Seegene Inc right now?
A high-quality business (quality 80/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case (29,136 KRW). The favourable scenario is already priced in.
Key figures of Seegene Inc
How large is the market capitalisation of Seegene Inc (096530)?
The market capitalisation of Seegene Inc is 1.4T KRW (≈ $1.0B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Seegene Inc (096530)?
The price-to-sales ratio of Seegene Inc is 2.77 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Seegene Inc (096530)?
Earnings per share at Seegene Inc are 2,014 KRW (price ÷ EPS = P/E 15.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Seegene Inc (096530)?
The dividend yield of Seegene Inc is 3.9% (payout 59.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Seegene Inc (096530)?
The net margin of Seegene Inc is 18.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Seegene Inc (096530)?
The return on equity (ROE) of Seegene Inc is 9.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Seegene Inc (096530)?
On an EBIT basis the return on assets of Seegene Inc is 11.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Seegene Inc (096530)?
The operating margin of Seegene Inc is 15.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Seegene Inc (096530)?
Revenue at Seegene Inc is growing +19.2% versus a year earlier (3y avg −17.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Seegene Inc (096530)?
Earnings per share at Seegene Inc are growing +101% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Seegene Inc in the live analysis
One click puts Seegene Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026